Drug
INCB057643 clinical trials
Also written SX-682.
- studies test it
- 13
- open now
- 9
- in phase 3
- 0
- first study started
- 2020
Keep track of what changes. Save the INCB057643 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- SX-682
- 18
Studies by the year they started
13 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2020 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 11
National Cancer Institute (NCI) (3) · University of Washington (2) · M.D. Anderson Cancer Center (1) · University of Rochester (1) · Incyte Corporation (1) · Lei Zheng (1) · Memorial Sloan Kettering Cancer Center (1) · Institute of Cancer Research, United Kingdom (1)
Often tested with
Tested in the same studies.
Nivolumab (2) · Bintrafusp alfa (1) · Atezolizumab (1) · Tislelizumab (1) · Apalutamide (1) · Daratumumab and Hyaluronidase-fihj (1) · Carfilzomib (1) · Dexamethasone (1)
Studies
Open first, then newest update. How each study uses INCB057643 is read from its arms, and is right about nine times in ten.
Testing it · 13
- Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT07667400Written as SX-682
- Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)RecruitingPhase 1/2National Cancer Institute (NCI)NCT06149481Written as SX-682
- SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung CancerRecruitingPhase 2University of WashingtonNCT07322341Written as CXCR1/2 Inhibitor SX-682
- A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas CancerRecruitingPhase 2Lei ZhengNCT05604560Written as SX-682
- A Study of SX-682 in Combination With Proton Craniospinal Irradiation (pCSI) in People With Leptomeningeal DiseaseRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07814352Written as SX-682
- Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate CancerRecruitingPhase 1/2Institute of Cancer Research, United KingdomNCT07002320Written as SX-682
- SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1Roswell Park Cancer InstituteNCT06622005Written as Cxcr1/2 Inhibitor SX-682
- SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung CancerRecruitingPhase 2University of WashingtonNCT05570825Written as CXCR1/2 Inhibitor SX-682
- Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate CancerRecruitingPhase 2Syntrix Biosystems, Inc.NCT06228053Written as SX-682
- SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 TrialActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT04599140Written as CXCR1/2 Inhibitor SX-682
- A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingPhase 1University of RochesterNCT04477343Written as SX-682
- A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy ParticipantsCompletedPhase 1Incyte CorporationNCT06941077Written as INCB057643
- Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)CompletedPhase 1/2National Cancer Institute (NCI)NCT04574583Written as SX-682
Given in every arm · 5 — INCB057643 is usual care beside what is tested
- Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic SyndromeRecruitingPhase 1Syntrix Biosystems, Inc.NCT04245397Written as SX-682
- Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsActive, not recruitingPhase 1Incyte CorporationNCT04279847Written as INCB057643
- SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With PembrolizumabActive, not recruitingPhase 1Syntrix Biosystems, Inc.NCT03161431Written as SX-682
- Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)TerminatedPhase 1/2Incyte CorporationNCT02959437Written as INCB057643
- Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesTerminatedPhase 1/2Incyte CorporationNCT02711137Written as INCB057643
Codes
What other systems call INCB057643 · ClinicalTrials.gg INT001512
- MeSH (NLM) C000712522INCB057643One source NLM
- UNII (FDA) H5212R2DPMSX-682Confirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000712522 | INCB057643 | One source NLM |
| UNII (FDA) | H5212R2DPM | SX-682 | Confirmed FDA, NLM |
Also registered as incb-057643 (UNII 87TZD0JEBS).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.